Seres Therapeutics (NASDAQ:MCRB) Announces Quarterly Earnings Results, Misses Expectations By $0.63 EPS

Seres Therapeutics (NASDAQ:MCRB) issued its quarterly earnings data on Wednesday. The biotechnology company reported ($1.63) earnings per share for the quarter, missing the consensus estimate of ($1.00) by ($0.63), FiscalAI reports. The firm had revenue of $0.59 million during the quarter, compared to the consensus estimate of $6.35 million. Seres Therapeutics had a negative net margin of 1,192.94% and a negative return on equity of 114.82%.

Seres Therapeutics Trading Down 0.5%

NASDAQ MCRB traded down $0.01 during trading on Wednesday, reaching $1.95. The company’s stock had a trading volume of 58,206 shares, compared to its average volume of 70,898. The stock has a market capitalization of $19.60 million, a PE ratio of -0.80 and a beta of 0.44. The business has a 50-day moving average price of $3.51 and a 200-day moving average price of $7.05. Seres Therapeutics has a 1-year low of $1.68 and a 1-year high of $29.98.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on MCRB shares. Wall Street Zen upgraded Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings cut shares of Seres Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, September 18th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $17.00.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc is a biotechnology company focused on developing live biotherapeutic products designed to restore the function of the human microbiome. The company’s platform uses defined communities of microorganisms rather than conventional fecal material to address diseases associated with microbiome disruption.

Seres’ lead product, VOWST (fecal microbiota spores, live-brpk), was approved by the U.S. Food and Drug Administration in 2023 to prevent the recurrence of Clostridioides difficile infection in adults following antibacterial treatment.